The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012

'The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012' is a new report from visiongain providing analysis of the current and future market for IBD drugs across all major indications. Forecasts are given based on new product launches, upcoming patent expiry dates, and ongoing clinical trials to enable you to predict changes in the dynamics of the global IBD market. Autoimmune disease is a multimillion dollar market set to increase as world prevalence rates rise and the population lives longer. Inflammatory bowel disease (IBD) affect millions of people worldwide with 2.8 million currently diagnosed with ulcerative colitis (UC) or Crohn’s disease (CD) in the US alone. The incidence of IBD is rising in developing countries around the world. Currently the global market is estimated at $16bn and this is set to continue to rise.

Historically, management of IBD with sulphonamides and corticosteroids did little to alter the course of disease and had severe side effects. In the 1990’s new therapies were introduced in the form of enteric coated aminosalicylates (5-ASA). From 3 drugs and one target in 1993 there are now more than 30 products and 10 targets. With the advent of monoclonal antibodies for use in IBD there has been a breakthrough in disease management which is set to expand rapidly over the next few years. Many more expensive biologicals are in the pipeline. As they gain approval and are prescribed in favour of cheaper options, revenues in the IBD market will grow rapidly.

- Will the current monoclonal blockbuster used to treat IBD continue to grow?

- What are the hottest research drugs in the pipeline?

- Will safety of issues restrict the use of biological agents in IBD?

Buy this report to find out!

Included in this report:

This report includes an up-to-date, analysis of IBD including the current market and possible future developments. The following important issues are covered in detail:

What new anti-inflammatory drugs are seeking the IBD indication

Unique analysed forecast for the biologicals market for IBD, 2007-2012

Summaries and revenue forecasts for the leading 5-ASA drugs, 2007-2012

Summaries and revenue for monoclonal antibody drugs, 2007-2012

A thorough examination of the biological pipeline for IBD including cytokine, chemokine and adhesion molecule antagonists

An assessment of future developments

You must order this report today.

Unique benefits to you when you order this report:

- Full searchable report when you buy the company or corporate editions

- Immediate access through our exclusive Reading Room

- You can access your report whichever country you are in without using harddrive space

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

If you buy one report this year make sure it is the report that will guarantee your success for the forthcoming years. Order this report now.

Publication Date: 06/02/07

Pages: 81

PDF Format
Table of Contents

Price
Single User Licence $2998.00
Department Licence 5 Users $5998.00
Company-wide Intranet Licence $9998.00